U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07033598) titled 'Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia' on June 05.
Brief Summary: The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are:
* Does pacritinib improve disease control compared to hydroxyurea?
* What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocyt...